Insider Transaction and Option Exercise

On August 5, 2026, Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, Inc. (NASDAQ:APGE), sold 5,500 shares of the company’s common stock at $134.17 per share, generating proceeds of $737,934. The sale was executed under a pre‑arranged Rule 10b5‑1 trading plan that the company adopted on September 22, 2025. At the time of the sale, Apogee’s share price was trading near its 52‑week high of $134.88, reflecting a 261% total return over the preceding year.

In the same transaction, Mr. Dambkowski exercised 4,125 stock options at an exercise price of $22.86 per share, resulting in an outlay of $94,297. These options were part of a larger grant giving him the right to purchase up to 175,345 shares, which will vest in forty‑eight equal monthly installments through December 18, 2027, contingent upon his continued service with the company. Following the sale and the option exercise, Mr. Dambkowski’s direct holdings consist of 168,498 shares of Apogee common stock and 110,665 outstanding stock options.

Acquisition Approval and Analyst Reactions

Apogee Therapeutics shareholders approved an acquisition agreement with AbbVie, valuing the company at $10.9 billion, or $135.11 per share. The announcement led several sell‑side analysts—including BTIG, Mizuho, and UBS—to downgrade the stock rating to Neutral from Buy. Mizuho raised its price target to $135 from $110, while UBS increased its target to $135.11 from $100, reflecting their assessment of the transaction’s fairness and its impact on valuation.

Strategic Partnership

In parallel, Apogee announced agreements with Paragon Therapeutics to discover and develop antibodies targeting the interleukin‑31 receptor. Under the agreements, Paragon will generate and characterize monospecific antibody candidates, and Apogee will provide compensation for these development activities.

Corporate Governance Update

The company’s recent annual meeting of stockholders resulted in the election of directors and the approval of various proposals, as disclosed in a recent SEC filing.